~~WHAT IS~~ CLAIM~~ED I~~S:

1. A composition comprising an effective amount of:

(a) about 0.3 mg/mL to about 30 mg/mL Antagonist A or a pharmaceutically acceptable salt thereof;

(b) about 0.5 mg/mL to about 20 mg/mL ranibizumab or a pharmaceutically acceptable salt thereof; and one or both of:

(c) a buffer capable of achieving or maintaining the pH of the composition at about pH 5.0 to about pH 8.0; and

(d) a tonicity modifier.

2. The composition of claim 1, wherein the buffer is about 1 mM to about 20 mM L-histidine or about 1 mM to about 20 mM sodium phosphate; and

the tonicity modifier is about 10 mM to about 200 mM NaCl, about 1% to about 20% (w/v) sorbitol, or about 1% to about 20% (w/v) trehalose.

3. The composition of claim 2, wherein the buffer is about 1 mM to about 20 mM L-histidine; and

the tonicity modifier is about 10 mM to about 200 mM NaCl.

4. The composition of any one of claims 1-3, further comprising:

(e) about 0.001% (w/v) to about 0.05% (w/v) surfactant.

5. The composition of claim 2, wherein the composition comprises:

(a) about 3 mg/mL Antagonist A or a pharmaceutically acceptable salt thereof;

(b) about 5 mg/mL ranibizumab or a pharmaceutically acceptable salt thereof;

(c) about 10 mM L-histidine; and

(d) about 130 mM NaCl,

wherein the pH of the composition is about pH 6.0.

6. The composition of claim 5, further comprising:

(e) about 0.01% (w/v) polysorbate 20.

7. The composition of claim 2, wherein the composition comprises:
(a) about 3 mg/mL Antagonist A or a pharmaceutically acceptable salt thereof;
(b) about 5 mg/mL ranibizumab or a pharmaceutically acceptable salt thereof;
(c) about 10 mM sodium phosphate; and
(d) about 5% (w/v) sorbitol,
wherein the pH of the composition is about pH 7.0.

8. The composition of claim 7, further comprising:
(e) about 0.01% (w/v) polysorbate 20.

9. The composition of claim 2, wherein the composition comprises:
(a) about 3 mg/mL Antagonist A or a pharmaceutically acceptable salt thereof;
(b) about 5 mg/mL ranibizumab or a pharmaceutically acceptable salt thereof;
(c) about 10 mM sodium phosphate; and
(d) about 130 mM NaCl,
wherein the pH of the composition is about pH 7.0.

10. The composition of claim 9, further comprising:
(e) about 0.01% (w/v) polysorbate 20.

11. The composition of claim 2, wherein the composition comprises:
(a) about 3 mg/mL Antagonist A or a pharmaceutically acceptable salt thereof;
(b) about 5 mg/mL ranibizumab or a pharmaceutically acceptable salt thereof;
(c) about 5 mM sodium phosphate;
(d) about 5 mM histidine HCl;
(e) about 75 mM NaCl; and
(f) about 5% (w/v) trehalose),
wherein the pH of the composition is about pH 6.5.

12. The composition of claim 11, further comprising:

(g) about 0.005% (w/v) polysorbate 20.

13. A composition comprising an effective amount of:

(a) about 0.3 mg/mL to about 30 mg/mL Antagonist A or a pharmaceutically acceptable salt thereof; and

(b) about 0.5 mg/mL to about 25 mg/mL bevacizumab or a pharmaceutically acceptable salt thereof; and one or both of:

(c) a buffer capable of achieving or maintaining the pH of the composition at about pH 5.0 to about pH 8.0; and

(d) a tonicity modifier.

14. The composition of claim 13, wherein the buffer is about 5 mM to about 200 mM sodium phosphate or about 5 mM to about 200 mM Tris.HCl; and

the tonicity modifier is about 10 mM to about 200 mM NaCl, about 1% to about 20% (w/v) sorbitol, or about 1% to about 20% (w/v) trehalose.

15. The composition of claim 14, wherein the buffer is about 5 mM to about 200 mM sodium phosphate; and

the tonicity agent is about 10 mM to about 200 mM NaCl,

wherein the pH of the composition is about pH 5.0 to about pH 7.0.

16. The composition of any one of claims 13-15, further comprising:

(e) about 0.001% (w/v) to about 0.05% (w/v) surfactant.

17. The composition of claim 14, wherein the composition comprises:

(a) about 3 mg/mL Antagonist A or a pharmaceutically acceptable salt thereof;

(b) about 12.5 mg/mL bevacizumab or a pharmaceutically acceptable salt thereof;

(c) about 50 mM sodium phosphate; and

(d) about 130 mM NaCl,

wherein the pH of the composition is about pH 6.0.

18. The composition of claim 17, further comprising:
(e) about 0.02% (w/v) polysorbate 20.

19. The composition of claim 14, wherein the composition comprises:
(a) about 3 mg/mL Antagonist A or a pharmaceutically acceptable salt thereof;
(b) about 12.5 mg/mL bevacizumab or a pharmaceutically acceptable salt thereof;
(c) about 50 mM sodium phosphate; and
(d) about 5% (w/v) sorbitol,
wherein the pH of the composition is about pH 6.0.

20. The composition of claim 19, further comprising:
(e) about 0.02% (w/v) polysorbate 20.

21. The composition of claim 14, wherein the composition comprises:
(a) about 3 mg/mL Antagonist A or a pharmaceutically acceptable salt thereof;
(b) about 12.5 mg/mL bevacizumab or a pharmaceutically acceptable salt thereof;
(c) about 50 mM sodium phosphate; and
(d) about 5% (w/v) sorbitol,
wherein the pH of the composition is about pH 7.0.

22. The composition of claim 21, further comprising:
e) about 0.02% (w/v) polysorbate 20.

23. The composition of claim 14, wherein the composition comprises:
(a) about 3 mg/mL Antagonist A or a pharmaceutically acceptable salt thereof;
(b) about 12.5 mg/mL bevacizumab or a pharmaceutically acceptable salt thereof;
(c) about 50 mM sodium phosphate; and
(d) about 150 mM NaCl,

wherein the pH of the composition is about pH 7.0.

24. The composition of claim 23, further comprising:
(e) about 0.02% (w/v) polysorbate 20.

25. The composition of claim 14, wherein the composition comprises:
(a) about 3 mg/mL Antagonist A or a pharmaceutically acceptable salt thereof;
(b) about 12.5 mg/mL bevacizumab or a pharmaceutically acceptable salt thereof;
(c) about 50 mM Tris.HCl; and
(d) about 130 mM NaCl,
wherein the pH of the composition is about pH 8.0.

26. The composition of claim 25, further comprising:
(e) about 0.02% (w/v) polysorbate 20.

27. The composition of claim 14, wherein the composition comprises:
(a) about 15 mg/mL Antagonist A or a pharmaceutically acceptable salt thereof;
(b) about 12.5 mg/mL bevacizumab or a pharmaceutically acceptable salt thereof;
(c) about 30 mM sodium phosphate;
(d) about 75 mM NaCl; and
(e) about 3% (w/v) trehalose,
wherein the pH of the composition is about pH 6.3.

28. The composition of claim 27, further comprising:
(f) about 0.02% (w/v) polysorbate 20.

29. The composition of claim 14, wherein the composition comprises:
(a) about 3 mg/mL Antagonist A or a pharmaceutically acceptable salt thereof;

(b) about 12.5 mg/mL bevacizumab or a pharmaceutically acceptable salt thereof;

(c) about 30 mM sodium phosphate;

(d) about 75 mM NaCl; and

(e) about 3% (w/v) trehalose,

wherein the pH of the composition is about pH 6.3.

30. The composition of claim 29, further comprising:

(f) about 0.02% (w/v) polysorbate 20.

31. A composition comprising an effective amount of:

(a) about 0.3 mg/mL to about 30 mg/mL Antagonist A or a pharmaceutically acceptable salt thereof;

(b) about 5 mg/mL to about 40 mg/mL aflibercept or a pharmaceutically acceptable salt thereof; and one or more of:

(c) a buffer capable of achieving or maintaining the pH of the composition at about pH 5.0 to about pH 8.0;

(d) a tonicity modifier; and

(e) 0 to about 10% (w/v) sucrose.

32. The composition of claim 31, wherein the buffer is about 5 mM to about 50 mM phosphate; and

the tonicity modifier is about 10 mM to about 200 mM NaCl.

33. The composition of claim 32, wherein the composition comprises:

(a) about 0.3 mg/mL to about 30 mg/mL Antagonist A or a pharmaceutically acceptable salt thereof;

(b) about 5 mg/mL to about 40 mg/mL aflibercept or a pharmaceutically acceptable salt thereof;

(c) about 5 mM to about 50 mM phosphate;

(d) about 10 mM to about 200 mM NaCl; and

(e) 0 to about 10% (w/v) sucrose,

wherein the pH of the composition is about pH 6.0 to about pH 8.0.

34. The composition of any one of claims 31-33, further comprising:

(f) about 0.001% (w/v) to about 0.05% (w/v) surfactant.

35. The composition of claim 32, wherein the composition comprises:

(a) about 6 mg/mL Antagonist A or a pharmaceutically acceptable salt thereof;

(b) about 40 mg/mL aflibercept or a pharmaceutically acceptable salt thereof;

(c) about 10 mM phosphate;

(d) about 40 mM NaCl; and

(e) about 5% (w/v) sucrose,

wherein the pH of the composition is about pH 6.2.

36. The composition of claim 35, further comprising:

(f) about 0.03% (w/v) polysorbate 20.

37. A composition comprising an effective amount of:

(a) about 3 mg/mL to about 90 mg/mL Antagonist A or a pharmaceutically acceptable salt thereof;

(b) about 1.0 mg/mL to about 30 mg/mL ranibizumab or a pharmaceutically acceptable salt thereof; and one or both of:

(c) a buffer capable of achieving or maintaining the pH of the composition at about pH 5.0 to about pH 8.0; and

(d) a tonicity modifier.

38. The composition of claim 37, wherein the buffer comprises about 1 mM to about 100 mM sodium phosphate or about 1.0 mM to about 10 mM histidine.HCl; and

the tonicity modifier is about 0.5% (w/v) to about 10% (w/v) trehalose.

39. The composition of claim 38, wherein the composition comprises:

(a) about 15 mg/mL Antagonist A or a pharmaceutically acceptable salt thereof;

(b) about 5 mg/mL ranibizumab or a pharmaceutically acceptable salt thereof;
(c) about 5 mM phosphate;
(d) about 75 mM NaCl;
(e) about 5 mM histidine.HCl; and
(f) about 5% (w/v) trehalose.

40. The composition of claim 39, further comprising:
(g) about 0.005% (w/v) polysorbate 20.

41. The composition of claim 38, wherein the composition comprises:
(a) about 24 mg/mL Antagonist A or a pharmaceutically acceptable salt thereof;
(b) about 8 mg/mL ranibizumab or a pharmaceutically acceptable salt thereof;
(c) about 8 mM phosphate;
(d) about 120 mM NaCl;
(e) about 2 mM histidine.HCl; and
(f) about 2% (w/v) trehalose.

42. The composition of claim 41, further comprising:
(g) about 0.002% (w/v) polysorbate 20.

43. ~~A~~ The composition of any one of claims 1 to 42 for use in a method for treating or preventing an ophthalmological disease~~, comprising administering to~~ in a mammal ~~in need thereof the composition of any one of claims 1, 13, 31 and 37~~.

44. The ~~method~~ composition for the use of claim 43, wherein the ophthalmological disease is age-related macular degeneration, polypoidal choroidal vasculopathy, condition associated with choroidal neovascularization, hypertensive retinopathy, diabetic retinopathy, sickle cell retinopathy, condition associated with peripheral retinal neovascularization, retinopathy of prematurity, venous occlusive disease, arterial occlusive disease, central serous chorioretinopathy, cystoid macular edema, retinal

telangiectasia, arterial macroaneurysm, retinal angiomatosis, radiation-induced retinopathy, rubeosis iridis, or a neoplasm.

45. The ~~method~~ composition for the use of claim 43, wherein the ophthalmological disease is wet age-related macular degeneration or dry age-related macular degeneration.

46. The ~~method~~ composition for the use of claim 43, wherein the composition is present in a drug-delivery device.

47. The ~~method~~ composition for the use of any one of claims 43-46, wherein the composition is for intraocular administ~~er~~ation~~ed intraocularly~~.

48. The ~~method~~ composition for the use of claim 47, wherein the intraocular administration is intravitreal administration or anterior chamber administration.

49. The ~~method~~ composition for the use of any one of claims 43-48, wherein the mammal is a human.

50. Use of the composition according to any one of claims 1 to 42 for the preparation of a medicament for treating or preventing an ophthalmological disease in a mammal.

51. Use of claim 50, wherein the ophthalmological disease is age-related macular degeneration, polypoidal choroidal vasculopathy, condition associated with choroidal neovascularization, hypertensive retinopathy, diabetic retinopathy, sickle cell retinopathy, condition associated with peripheral retinal neovascularization, retinopathy of prematurity, venous occlusive disease, arterial occlusive disease, central serous chorioretinopathy, cystoid macular edema, retinal telangiectasia, arterial macroaneurysm, retinal angiomatosis, radiation-induced retinopathy, rubeosis iridis, or a neoplasm.

52. Use of claim 50, wherein the ophthalmological disease is wet age-related macular degeneration or dry age-related macular degeneration.

53. Use of any one of claims 50 to 52, wherein the medicament is for intraocular administration.

54. Use according to claim 53, wherein the intraocular administration is intravitreal administration or anterior chamber administration.

55. Use according to any one of claims 50 to 54, wherein the mammal is a human.